

Kansas City University

DigitalCommons@KCU

Student Publications

Research@KCU

4-2022

It is Not the Time to Relax Yet: Masks are Still Needed for the Omicron Variant of SARS-CoV-2

Scott Lowe

Ruijin Xie

Yue Chen

Yifan Shen

Chenyu Sun

Follow this and additional works at: <https://digitalcommons.kansascity.edu/studentpub>



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the Editor

It is not the time to relax yet: masks are still needed for the Omicron variant of SARS-CoV-2



Since the first case of Coronavirus disease 2019 (COVID-19) was found in Wuhan, China, on December 31, 2019, this pandemic went on to affect more than 267 million people worldwide.¹ Although the Delta variant remains the leading cause of infection, the Omicron (B.1.1.529) variant of concern, which is associated with enhanced transmissibility and evasion to vaccine-induced immunity, now emerged as a new public health threat.^{2,3}

Currently, 25.7% of fully vaccinated Americans received their boosters as of December 2021.⁴ However, alterations of 37 amino acids in the Spike (S) protein in Omicron variant may have rendered it with resistance and blunts the potency of neutralizing antibodies.⁵ A recent study by Cele et al. from Africa Health Research Institute has indicated the Omicron escapes antibody neutralization elicited by the Pfizer BNT162b2 mRNA vaccine by 41-fold in comparison to ancestral D614G in FRNT50 assay.⁶ Also, to investigate immune evasion mediated by Omicron, researchers from Vir Biotechnology, Switzerland, have compared the variant's neutralizing ability in all existing vaccines (mRNA-1273, BNT162b2, AZD1222, Ad26.COV2.S, SputnikV, BBIBP-CorV) using plasma obtained from COVID-19 convalescent or vaccinated individuals. It has found mRNA-1273 (Moderna) exhibits highest neutralization of Omicron followed by BNT162b2 (Pfizer), with Sputnik V (Russia) showing diminished to non-existent neutralization.⁷ Meanwhile, another recent study found that in comparison to Delta variant, Omicron replicates and infects 70 times faster in human bronchus.⁸ Although the vaccines protect people well against severe progression of the disease, its effectiveness on prevention of the new Omicron variant remains under investigation. Therefore, non-pharmaceutical interventions (NPIs), such as mask-wearing, remain essential to mitigate the COVID-19 infection. Recently, a 6-month-long cluster-randomized trial has revealed intervention measures to make people wear surgical mask correctly can reduce the prevalence ratio (PR) for COVID by 11%; the outcome has most significant impact for age group >60 as it successfully reduced the PR by 35%.⁹ According to a recent published meta-analysis, mask-wearing reduces the risk of COVID-19 infection by 81%.¹⁰ These studies indicate that mask provides an additional low-cost and easy-to-implement physical barrier to effectively minimize the infection risk of severe acute respiratory coronavirus 2.

In conclusion, while it is important to continue promoting the vaccination among population in developing countries and under-served areas, mask-wearing and other NPIs are still effective

preventive methods with low cost and easy access in current COVID-19 pandemic, especially with the emergence of the more infectious Omicron variant.

References

1. WHO coronavirus (COVID-19) dashboard. World Health Organization (WHO) website. 2021. <https://covid19.who.int/>. [Accessed 11 December 2021].
2. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* 2021;19(7):409–24. <https://doi.org/10.1038/s41579-021-00573-0>.
3. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. *Cell Host Microbe* 2021;29(1):44–57.e9. <https://doi.org/10.1016/j.chom.2020.11.007>.
4. Bajema KL, Dahl RM, Evener SL, Prill MM, Rodriguez-Barradas MC, Marconi VC, et al. Comparative effectiveness and antibody responses to Moderna and Pfizer-BioNTech COVID-19 vaccines among hospitalized veterans - five veterans affairs medical centers, United States, February 1-September 30, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(49):1700–5. <https://doi.org/10.15585/mmwr.mm7049a2>. Published 2021 Dec 10. [Accessed 11 December 2021].
5. Wang R, Chen J, Wei GW. Mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America [in press] *J Phys Chem Lett* 2021:11850–7. <https://doi.org/10.1021/acs.jpcclett.1c03380>.
6. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT 162b2 elicited neutralization and requires ACE2 for infection. *MedRxiv* 2021. <https://doi.org/10.1101/2021.12.08.21267417>. 12.08.21267417. Preprint.
7. Cameroni E, Saliba C, Bowen JE, Rosen LE, Culp K, Pinto D, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *bioRxiv* 2021. <https://doi.org/10.1101/2021.12.12.472269>. 12.12.472269. Preprint.
8. HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in Lung. Dec 2021. <https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection>. Accessed Dec 2021.
9. Abaluck J, Kwong LH, Styczynski A, Haque A, Kabir MA, Bates-Jefferys E, et al. Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh. *Science* 2022;375(6577):eabi9069. <https://doi.org/10.1126/science.abi9069>.
10. Li Y, Liang M, Gao L, Ayaz Ahmed M, Uy JP, Cheng C, et al. Face masks to prevent transmission of COVID-19: a systematic review and meta-analysis. *Am J Infect Control* 2021;49(7):900–6. <https://doi.org/10.1016/j.ajic.2020.12.007>.

Scott Lowe
College of Osteopathic Medicine, Kansas City University, Kansas City,
MO, United States

Ruijin Xie
Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China

Yue Chen
Department of Clinical Medicine, School of the First Clinical Medicine,
Anhui Medical University, Hefei, Anhui, China

Yifan Shen
*Department of Emergency Medicine, Shanghai Municipal Hospital of
Traditional Chinese Medicine, Shanghai University of Traditional
Chinese Medicine, Shanghai, China*

Chenyue Sun*
*Internal Medicine, AMITA Health Saint Joseph Hospital Chicago,
Chicago, IL, United States*

* Corresponding author.
E-mail address: drsunchenyue@yeah.net (C. Sun).

4 January 2022
Available online 2 February 2022